Supplement Maker Lands FDA Warning Letter for GMP Violations, Drug-like Claims

Drug Industry Daily
A A
A California supplement maker is drawing scrutiny from the FDA for violating GMP regulations and misbranding products as drugs.

To View This Article:

Login

Subscribe To Drug Industry Daily